Posts by: Joana Carvalho, PhD

Joana Carvalho, PhD

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

October 12, 2020October 12, 2020

NCI Awards $1.7M for Bone Therapy Research to Prevent or Delay Cancer Relapse

News

The National Cancer Institute (NCI) has awarded $1.7 million to support the work of a University of Arkansas for Medical Sciences (UAMS) researcher in developing a therapy that can ... Read more

September 23, 2020September 23, 2020

Ide-cel Granted FDA Priority Review for Heavily-treated Multiple Myeloma

News

The U.S. Food and Drug Administration (FDA) has granted priority review to Bristol Myers Squibb and Bluebird Bio‘s application requesting the approval of idecabtagene vicleucel (ide-cel) for the treatment of adults with ... Read more

September 14, 2020September 14, 2020

FDA Puts on Hold Phase 1 Cellectis Trial Testing CAR T-cell Therapy UCARTCS1A

News

A Phase 1 trial assessing Cellectis’ investigational CAR T-cell therapy, UCARTCS1A, for the treatment of relapsed or refractory multiple myeloma has been placed on hold by the U.S. Food and ... Read more

July 20, 2020August 6, 2020

FDA Office Favors Antibody-drug Conjugate for Advanced Multiple Myeloma

News

An office of the U.S. Food and Drug Administration (FDA) has recommended that belantamab mafodotin, GlaxoSmithKline’s investigational antibody-drug conjugate, be approved for heavily pretreated relapsed or refractory multiple myeloma patients. ... Read more

July 16, 2020July 16, 2020

Reolysin-Kyprolis Combo Elicits Promising Clinical Responses in Phase 1B Trial

News

When given in combination with Kyprolis (carfilzomib), the investigative therapy Reolysin (pelareorep) elicits a strong inflammatory response — and promising clinical responses — in people with relapsed or refractory multiple myeloma, a ... Read more

June 26, 2020June 26, 2020

Oncopeptides Reports Positive Results from HORIZON Trial of Melflufen Combo

News

The combination therapy of melflufen (melphalan flufenamide) and dexamethasone continues to be safe and to elicit deep and durable responses in hard-to-treat patients with relapsed or refractory multiple myeloma, ... Read more

June 24, 2020August 6, 2020

Belantamab Mafodotin Continues to Show Promise in Advanced Myeloma Trials

News

Belantamab mafodotin, GlaxoSmithKline’s investigational antibody-drug conjugate, continues to show promise when used alone or in combination with other approved therapies to treat people with relapsed or refractory multiple myeloma, ... Read more

June 22, 2020June 22, 2020

JNJ-4528 Continues to Show Strong, Durable Responses in Trial

News

Janssen’s investigational CAR T-cell therapy for multiple myeloma, called JNJ-4528, continues to lead to strong and durable responses in all patients with relapsed or refractory disease who are participating ... Read more

June 12, 2020June 12, 2020

Xpovio Triple Combo Before FDA for Previously Treated Myeloma Patients

News

Karyopharm Therapeutics is asking that Xpovio (selinexor) be approved with Velcade (bortezomib) and low-dose dexamethasone to treat people with multiple myeloma after at least one line of therapy. The request ... Read more

June 5, 2020June 5, 2020

New Under-the-skin Darzalex Formulation Approved in EU

News

The European Commission (EC) has approved a new under-the-skin (subcutaneous), fixed-dose formulation of Janssen’s Darzalex (daratumumab) for the treatment of adults with multiple myeloma. The approval of the new ... Read more

Pin It on Pinterest